Abstract
Previous attempts have shown the potential of T cells in immunotherapy of cancer. Here, we report on the clinical activity of a bispecific antibody construct called blinatumomab, which has the potential to engage all cytotoxic T cells in patients for lysis of cancer cells. Doses as low as 0.005 milligrams per square meter per day in non-Hodgkin's lymphoma patients led to an elimination of target cells in blood. Partial and complete tumor regressions were first observed at a dose level of 0.015 milligrams, and all seven patients treated at a dose level of 0.06 milligrams experienced a tumor regression. Blinatumomab also led to clearance of tumor cells from bone marrow and liver. T cell-engaging antibodies appear to have therapeutic potential for the treatment of malignant diseases.
Publication types
-
Clinical Trial, Phase I
-
Multicenter Study
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antibodies, Bispecific / administration & dosage*
-
Antibodies, Bispecific / adverse effects
-
Antibodies, Bispecific / immunology
-
Antibodies, Bispecific / therapeutic use
-
Antineoplastic Agents / administration & dosage*
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use
-
B-Lymphocytes / immunology
-
Humans
-
Immunologic Memory
-
Immunophenotyping
-
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy
-
Leukemia, Lymphocytic, Chronic, B-Cell / immunology
-
Lymphocyte Count
-
Lymphoma, B-Cell / drug therapy*
-
Lymphoma, B-Cell / immunology
-
Lymphoma, Follicular / drug therapy*
-
Lymphoma, Follicular / immunology
-
Lymphoma, Mantle-Cell / drug therapy*
-
Lymphoma, Mantle-Cell / immunology
-
Recurrence
-
T-Lymphocytes / immunology
-
T-Lymphocytes, Cytotoxic / immunology*
Substances
-
Antibodies, Bispecific
-
Antineoplastic Agents
-
blinatumomab